810659-05-3

Usage

Uses

Used in Pharmaceutical Industry:
Cyclohexanemethanamine, 4,4-difluorois used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique fluorinated structure contributes to the development of new drugs with improved properties, such as enhanced bioavailability and targeted therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, Cyclohexanemethanamine, 4,4-difluorois used as a building block for the creation of novel agrochemicals. Its incorporation into these compounds can lead to more effective and targeted pest control solutions, as well as reduced environmental impact.

InChI:InChI=1/C7H13F2N/c8-7(9)3-1-6(5-10)2-4-7/h6H,1-5,10H2

Upstream product

• 176251-49-3 8,8-difluoro-1,4-dioxaspiro[4,5]decane 
• 60-29-7 diethyl ether 
• 22515-18-0 4,4-difluorocyclohexanone 
• 1122648-78-5 4-(azidomethyl)-1,1-difluorocyclohexane 
• 809273-64-1 tert-butyl (4,4-difluorocyclohexyl)methylcarbamate 
• 809273-70-9 (4-oxo-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 
• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 927209-98-1 4,4-difluorocyclohexanecarboxamide 
• 922728-21-0 4,4-difluorocyclohexane-1-carbonitrile 

Downstream Products

• 1062653-75-1 C₂₀H₂₃ClF₂N₄O 
• 1361951-02-1 N-((4,4-difluorocyclohexyl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 

Relevant academic research and scientific papers

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors

We describe here a novel 4-amino-2-cyanopyrimidine scaffold for nonpeptidomimetic cathepsin S selective inhibitors. Some of the synthesized compounds have sub-nanomolar potency and high selectivity toward cathepsin S along with promising pharmacokinetic a

A PROCESS FOR PRODUCING [(4,4- DIF LUOROCYCLOHEXYL) METHYL] AMINE

A process for preparing a compound of formula I wherein R1 is H, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, -OH, or amino; and n, m, and p are independently selected from 0, 1 and 2; which process comprises reacting a

SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula (I), wherein R1 is a ring, R5 is a specified substituent, and n is from 1 to 8. The invention also relates to the use of the compounds in therapy as metabotropic glutamate receptors modulators, particularly in neurological and psychiatric disorders.

PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES.

The present invention relates to a process of preparing a compound of formula II, wherein R1, n, m and p are defined in the specification.

Substituted benzothiazole amide derivatives

A compound of formula I and a method of treatment of diseases, related to modulation of the adenosine A2 receptor system comprising administering a compound of formula 1to a person in need of such treatment.